Copyright
©2010 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 21, 2010; 16(35): 4400-4409
Published online Sep 21, 2010. doi: 10.3748/wjg.v16.i35.4400
Published online Sep 21, 2010. doi: 10.3748/wjg.v16.i35.4400
Table 1 Characteristics of 938 chronic hepatitis C genotype 1 patients treated with a combination of pegylated interferon plus ribavirin according to age (mean ± SD)
Group A (age < 65 yr) (n = 685) | Group B (age≥65 yr) (n = 253) | P-value | |
Age (yr) | 53.1 ± 8.9 | 68.6 ± 3.1 | < 0.001 |
Male/female | 374/311 | 122/131 | 0.090 |
Body mass index (kg/m2) | 23.7 ± 3.3 | 22.8 ± 2.7 | < 0.001 |
Prior IFN monotherapy, n (%) | 163 (23.8) | 76 (30.0) | 0.052 |
Prior combined IFN plus RBV treatment, n (%) | 51 (7.4) | 20 (7.9) | < 0.001 |
Alanine aminotransferase (IU/L) | 80.2 ± 62.0 | 67.9 ± 46.6 | 0.004 |
γ-glutamyltranspeptidase (IU/L) | 60.2 ± 56.6 | 57.1 ± 49.2 | 0.708 |
Albumin (g/dL) | 4.1 ± 0.4 | 4.0 ± 0.4 | < 0.001 |
White blood cell count (/mm3) | 5200.0 ± 1476.7 | 4756.3 ± 1458.9 | < 0.001 |
Hemoglobin (g/dL) | 14.1 ± 1.4 | 13. 5 ± 1.4 | < 0.001 |
Platelet count (109/L) | 16.6 ± 5.3 | 15.0 ± 5.2 | < 0.001 |
Creatinine (mg/dL) | 0.7 ± 0.6 | 0.8 ± 1.4 | 0.107 |
Creatinine clearance (mL/min) | 105.5 ± 28.7 | 75.8 ± 17.5 | < 0.001 |
Serum HCV-RNA level (kIU/mL) | 1776.1 ± 1500.0 | 1986.9 ± 1604.5 | 0.125 |
Histological fibrosis | 0.008 | ||
F0/F1/F2/F3/F4 | 36/155/121/61/30 | 9/46/49/31/17 |
Table 2 Characteristics of 313 chronic hepatitis C genotype 2 patients treated with a combination of pegylated interferon plus ribavirin according to age (mean ± SD)
Group C (age < 65 yr) (n = 252) | Group D (age≥65 yr) (n = 61) | P-value | |
Age (yr) | 47.7 ± 10.4 | 69.2 ± 3.4 | < 0.001 |
Male/female | 124/128 | 28/33 | 0.671 |
Body mass index (kg/m2) | 23.1 ± 3.5 | 22.8 ± 2.9 | 0.577 |
Prior IFN monotherapy, n (%) | 47 (18.7) | 16 (26.2) | < 0.001 |
Prior combined IFN plus RBV treatment, n (%) | 5 (2.0) | 4 (6.6) | 0.056 |
Alanine aminotransferase (IU/L) | 79.9 ± 78.7 | 68.9 ± 52.9 | 0.821 |
γ-glutamyltranspeptidase (IU/L) | 55.8 ± 64.7 | 44.3 ± 34.7 | 0.937 |
Albumin (g/dL) | 4.2 ± 0.4 | 3.9 ± 0.5 | < 0.001 |
White blood cell count (/mm3) | 5276.3 ± 1636.3 | 4958.0 ± 1495.6 | 0.005 |
Hemoglobin (g/dL) | 14.1 ± 1.4 | 13.4 ± 1.3 | < 0.001 |
Platelet count (109/L) | 18.9 ± 6.3 | 15.6 ± 4.7 | < 0.001 |
Creatinine (mg/dL) | 0.8 ± 1.5 | 0.7 ± 0.2 | 0.581 |
Creatinine clearance (mL/min) | 112.1 ± 31.4 | 74.6 ± 17.2 | < 0.001 |
Serum HCV-RNA level (kIU/mL) | 1588.3 ± 1628.7 | 1195.4 ± 1645.5 | 0.038 |
Histological fibrosis | < 0.001 | ||
F0/F1/F2/F3/F4 | 30/77/39/10/10 | 1/21/9/2/12 |
Table 3 The comparison of the rate of sustained virological response of patients with genotype 1 receiving a dose of 80% or more of pegylated interferon α-2b plus 60% or more of ribavirin and the reduced dosage group n (%)
Male | Female | Total | ||||
n | SVR | n | SVR | n | SVR | |
Group A | ||||||
Minimum acceptable | 168 | 116 (69.0) | 110 | 69 (62.7) | 278 | 185 (66.5) |
Reduced | 206 | 73 (35.4) | 201 | 66 (32.8) | 407 | 139 (34.2) |
Total | 374 | 189 (50.5) | 311 | 135 (43.4) | 685 | 324 (47.3) |
Group B | ||||||
Minimum acceptable | 31 | 15 (48.4) | 31 | 13 (41.9) | 62 | 28 (45.2) |
Reduced | 91 | 18 (19.8) | 100 | 12 (12.0) | 191 | 30 (15.7) |
Total | 122 | 33 (27.0) | 131 | 25 (19.1) | 253 | 58 (22.9) |
Table 4 Reasons for discontinuation of pegylated interferon plus ribavirin treatment by hepatitis C virus genotype 1 patients
Group A (age < 65 yr) | Group B (age≥65 yr) | Total | |||
Male (n = 374) | Female (n = 311) | Male (n = 122) | Female (n = 131) | ||
Discontinued number | 101 | 66 | 52 | 54 | 273 |
Adverse effects | 43 | 31 | 33 | 28 | 135 |
General fatigue | 17 | 7 | 12 | 11 | 47 |
Depression | 3 | 11 | 4 | 5 | 23 |
Appetite loss | 1 | 0 | 1 | 0 | 2 |
Rash | 3 | 2 | 3 | 4 | 12 |
Encephalopathy | 1 | 0 | 0 | 0 | 1 |
Neutropenia | 2 | 0 | 0 | 0 | 2 |
Anemia | 3 | 2 | 4 | 1 | 10 |
Thrombocytopenia | 1 | 0 | 3 | 1 | 5 |
Elevation of ALT | 1 | 0 | 0 | 0 | 1 |
Hyperthyroidism | 3 | 2 | 0 | 1 | 6 |
Hypothyroidism | 0 | 1 | 0 | 0 | 1 |
Retinopathy | 1 | 0 | 1 | 0 | 2 |
Interstitial pneumonia | 2 | 0 | 1 | 1 | 4 |
Pulmonary disease (others)1 | 0 | 1 | 1 | 1 | 3 |
Psychoneurotic disorder2 | 2 | 0 | 2 | 0 | 4 |
Nervous disease3 | 1 | 1 | 0 | 1 | 3 |
Autoimmune disease4 | 0 | 2 | 0 | 1 | 3 |
Metabolic disease5 | 0 | 2 | 0 | 0 | 2 |
Digestive disorder6 | 2 | 0 | 1 | 1 | 4 |
Hepatocellular carcinoma | 2 | 0 | 4 | 1 | 7 |
Malignancy (extra-liver) | 0 | 1 | 1 | 0 | 2 |
No effect of treatment | 22 | 18 | 7 | 8 | 55 |
Economic problem | 9 | 3 | 0 | 3 | 15 |
Others7 | 25 | 13 | 7 | 14 | 59 |
Table 5 Reasons for discontinuation of pegylated interferon plus ribavirin treatment by hepatitis C virus genotype 2 patients
Group C (age < 65 yr) | Group D (age≥65 yr) | Total | |||
Male (n = 124) | Female (n = 128) | Male (n = 28) | Female (n = 33) | ||
Discontinued number | 18 | 15 | 4 | 4 | 41 |
Adverse effects | 6 | 11 | 3 | 3 | 23 |
General fatigue | 1 | 3 | 1 | 0 | 5 |
Depression | 0 | 2 | 0 | 0 | 2 |
Appetite loss | 0 | 0 | 0 | 0 | 0 |
Rash | 2 | 1 | 0 | 2 | 5 |
Encephalopathy | 0 | 0 | 0 | 1 | 1 |
Neutropenia | 0 | 2 | 0 | 0 | 2 |
Anemia | 0 | 0 | 2 | 0 | 2 |
Thrombocytopenia | 2 | 0 | 0 | 0 | 2 |
Elevation of ALT | 0 | 0 | 0 | 0 | 0 |
Hyperthyroidism | 0 | 1 | 0 | 0 | 1 |
Hypothyroidism | 0 | 1 | 0 | 0 | 1 |
Retinopathy | 0 | 0 | 0 | 0 | 0 |
Interstitial pneumonia | 0 | 0 | 0 | 0 | 0 |
Pulmonary disease(others) | 0 | 0 | 0 | 0 | 0 |
Psychoneurotic disorder | 0 | 0 | 0 | 0 | 0 |
Nervous disease1 | 1 | 1 | 0 | 0 | 2 |
Autoimmune disease | 0 | 0 | 0 | 0 | 0 |
Metabolic disease | 0 | 0 | 0 | 0 | 0 |
Digestive disorder | 0 | 0 | 0 | 0 | 0 |
Hepatocellular carcinoma | 0 | 0 | 0 | 0 | 0 |
Malignancy (extra-liver) | 1 | 0 | 0 | 0 | 1 |
No effect of treatment | 1 | 0 | 0 | 0 | 1 |
Economic problem | 0 | 0 | 0 | 0 | 0 |
Others2 | 10 | 4 | 1 | 1 | 16 |
- Citation: Kainuma M, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Shimono J, Shimoda S, Hayashi J, Group TKULDS. Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C. World J Gastroenterol 2010; 16(35): 4400-4409
- URL: https://www.wjgnet.com/1007-9327/full/v16/i35/4400.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i35.4400